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Cisplatin has been for many years the gold standard chemotherapeutic drug for the treatment of 28 
a wide range of solid tumors, even though its use is commonly associated with serious side 29 
effects including non-selective toxicity, myelosuppression or development of cisplatin 30 
resistance, among others complications. Over the last decade, a number of nanoparticle 31 
formulations were developed to reduce its side effects and improve the selectivity and efficacy 32 
of this drug.  In this study, we have developed a novel nanoparticle platform based on nanoscale 33 
coordination polymer named (Zn-Pt(IV)-NCPs) which contains a Pt(IV) prodrug , Zn and the 34 
linker ligand 1,4-Bis(imidazol-1-ylmethyl)benzene (bix). The main objective has been to gain 35 
insights into the mechanism of action of this nanostructured material in comparison with 36 
cisplatin and the free Pt(IV) prodrug in order to stablish a correlation between nanostructuration 37 
and therapeutic activity. Zn-Pt(IV)-NCPs  nanoparticles displayed an average size close to 200 38 
nm as determined by DLS, a good stability in physiologic environments, and a controlled drug 39 
release of Pt. In vitro studies demonstrated that Pt(IV)-NCPs showed an enhanced cytotoxic 40 
effect against cell culture of  cervical cancer, neuroblastoma and human adenocarcinoma cells in 41 
comparison with free Pt(IV) prodrug. Although no difference in cell uptake of Pt was observed 42 
for any of the three cell lines assayed, a higher amount of Pt bound to the DNA was found in the 43 
cells treated with the nanostructured Pt(IV) prodrug. These studies suggest that the 44 
nanostructuration of the prodrug facilitate its activation and induce a change in the mechanism 45 
of action related to an increased interaction with the DNA as corroborated by the studies of 46 
direct interaction of the Pt(IV) prodrug, nanostructured or not, with DNA.  47 
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1. Introduction  53 
Cisplatin, also termed as cis-diaminedichloroplatinum (II) or CDDP, is one of the most widely 54 
known and effective drugs used in chemotherapy [1]. This platinum (II)-based molecule is a 55 
coordination complex capable to induce cellular apoptosis due to its ability to form intrastrand 56 
crosslinks and other adducts with DNA [2, 3]. After its FDA approval in 1978, it has been used 57 
for treatment of a variety of human solid tumors, including bladder, head and neck, non-small 58 
cell lung cancer (NSCLC), small cell lung cancer (SCLC), ovarian, testicular cancers and 59 
neuroblastoma, among others [3]. Although cisplatin is the first-line treatment for the majority 60 
of these cancers, the administration of this drug presents many drawbacks. One of the most 61 
important is the lack of tumor tissue selectivity leading to important side effects including 62 
nephrotoxicity, ototoxicity and or neurotoxicity [4-6]. Moreover, the administration of high 63 
doses over time may cause myelosuppression and acquired drug resistance [7, 8]. To overcome 64 
such limitations, a series of new cisplatin analogues have been synthetized, and six of them have 65 
gained marketing approval over the last thirty years [9]. However, there are still severe side 66 
effects associated with the use of these drugs, which notably limit their administration and 67 
clinical effectiveness [9, 10].  68 
 69 
During the last decade, a variety of nanostructured systems have been developed as carriers to 70 
improve the therapeutic efficacy and decrease the toxicity of cisplatin and cisplatin analogues 71 
[11-14]. These systems include organic, inorganic and hybrid nanoparticles. Typically such 72 
systems follow two different strategies for drug loading; 1) the direct encapsulation of the drug 73 
by physical entrapment; 2) incorporation of the active molecule as building block. Among 74 
hybrid nanoparticles, Nanostructured Coordination Polymers (NCPs) present important and 75 
unique features, such as its chemical tunability, intrinsic biodegradability and high drug loading 76 
capacity. In addition, these nano-platforms have demonstrated promising preclinical results, 77 
since exploit what is called the enhanced permeability and retention (EPR) effect [15] and 78 
display more controlled and efficient drug release profiles [16, 17]. NCPs are nanoparticles 79 
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made from the coordination of a metal ion or metal complex that can be polymerized by using 80 
adequate linker ligands [17-19]. In these systems, the therapeutic specie can be encapsulated 81 
during the nanoparticles formation or act as building blocks what determines the release rate of 82 
the active specie [17]. One of the methodologies used for minimize the side effects of cisplatin 83 
derivatives is to use the oxidized form Pt(IV) as inactive prodrug molecule. These Pt(IV) 84 
complexes remains inactive in physiological conditions meanwhile in intracellular conditions it 85 
can become into the pharmacologically active Pt(II) form by the action of reducing agents (i.e. 86 
ascorbic acid (AA) or glutathione) [14]. The transformation of the square-planar Pt(II) species 87 
into Pt(IV) octahedral complexes has a valuable benefit since this geometry allow polymerize 88 
the Pt(IV) units through the axial positions as previously reported [14]. The first family of 89 
Pt(IV)-based NCPs was developed by Lin and coworkers in 2008, by using disuccinatocisplatin 90 
(DSCP) as Pt(IV) prodrug. This novel strategy for delivery of Pt-based drugs demonstrated 91 
unprecedented chemotherapeutic efficiency towards two different cancer cell lines in vitro [16]. 92 





 metal ions and the DSCP ligand as main building block, obtaining 94 
spherical nanoparticles, with a controlled drug release of cisplatin and with enhanced cytotoxic 95 
effects against two small cell lung cancer cell lines [20]. Additionally, when these lipid-coated 96 
nanoparticles were functionalized with anisamide, an enhanced uptake of the nanoparticles was 97 
further demonstrated by confocal microscopy and binding assays [20]. From these seminal 98 
works, a series of lipid coated and pegalyted NCPs derived from zinc phosphate and cisplatin or 99 
oxaliplatin Pt(IV) prodrug were tested in vivo in mice, in both cases showing superior antitumor 100 
activity compared with free drugs [21]. Although the large number of studies that have been 101 
performed with Pt(IV)-based NCPs, there is a lack of knowledge concerning the action 102 
mechanisms of the Pt(IV) prodrugs and the effect of its nanostructuration. In this scenario, our 103 





Hence, in this work, novel Pt(IV) prodrug-based nanostructured coordination polymer particles, 107 
termed Zn-Pt(IV)-NCPs, were synthetized and extensively characterized. The stability of the 108 
nanoparticles, as well as the Pt release, were studied under physiologic conditions. We have also 109 
studied the interaction of the released platinum species with DNA by electrophoretic mobility 110 
measurements. Additionally, the Pt uptake and the amount of Pt bound to the DNA in three 111 
different tumor cell lines were assessed comparing the nanoparticles with the free Pt(IV) 112 
prodrug. The cytotoxicity associated to the nanoparticles was demonstrated on multiple cancer 113 
cell lines in vitro and compared to the free Pt(IV) prodrug. The results obtained in this study 114 
provide important evidences of the influence of the nanostructuration on the biological 115 
effectiveness of Pt(IV) prodrugs at cellular level.  116 
 117 
2. Materials and Methods  118 
2.1 Materials 119 
All chemical reagents were purchased from Sigma-Aldrich (unless otherwise specified) and 120 
used as received. Solvents were obtained from Scharlab and used as received. Cell culture 121 
media and culture media supplements were ordered from Life Technologies. 1,4-Bis(imidazol-122 
1-ylmethyl)benzene (bix) was synthesized as previously reported by our group with some 123 
modifications (see Supporting Information, A1) [22, 23]. ICP-MS standards and the setup 124 
solution were acquired from Perkin Elmer. PrestoBlue
TM
 Cell Viability reagent was purchased 125 
from Invitrogen. All the nanoparticles synthetized in the present work were prepared under 126 
general aseptic conditions to ensure the suitability of the final material for biological 127 
experiments. All the cell lines were obtained from the American Type Culture Collection 128 





2.2 Characterization methods 132 
FT-IR spectra were recorded by using a Tensor 27 spectrophotometer (Buker) equipped with a 133 
single-reflection diamond window ATR accessory (MKII Golden Gate, Specac). 250 MHz 
1
H 134 
NMR spectra were recorded on a Bruker DPX 250 MHz spectrometer; Powder X-ray diffraction 135 
(XRD) pattern was recorded on a X’Pert PRO MRD diffractometer (PANalytical) and X-ray 136 
photoelectron spectroscopy (XPS) was performed in a Phoibos 150 analyser from SPECS. A 137 
NexION 300X ICP mass spectrometer (PerkinElmer) was used for mass spectrometry 138 
measurements. Scanning electron microscopy (SEM) images were captured on a Quanta 650 139 
FEG microscope (FEI) at acceleration voltages of 5–20 kV. Previously, the samples were 140 
prepared by drop casting of the corresponding dispersion on aluminum tape followed by 141 
evaporation of the solvent under room conditions. All the samples were metalized with a thin 142 
layer of platinum (5 nm) by using a Quorum Emitech K550 (Quorum technologies Ltd). 143 
Scanning transmission electron microscopy (STEM) images were acquired on a FEI Tecnai F20 144 
transmission electron microscope with a HAADF detector at an applied boltage of 75 kV. 145 
Dynamic light scattering (DLS) analysis were performed with a Zetasizer Nano 3600 (Malvern 146 
instruments) in a PBS buffer containing 31 mg/ml Bovine Serum Albumin (BSA). Fluorescent 147 
images from the nanoparticles were acquired using an Axio-Observer Microscope from Zeiss 148 
equipped with a AxioCam HRc camera. A Victor3 fluorescence reader (PerkinElmer’s) was 149 
used to read the plates in the cytotoxicity assays. A GelDoc XR+ reader from Bio-Rad was used 150 
for imaging of agarose gels. An Agilent HP 8453 UV-vis spectrophotometer was used for DNA 151 
quantification.  152 
 153 
2.3 Synthesis of the Pt(IV) prodrug 154 
The Pt(IV) prodrug was synthetized similarly as previously described [16], with some 155 
modifications. Briefly, the Pt(IV) prodrug was prepared through three synthetic steps: 1) The 156 
first step starts with the oxidation of cisplatin to oxoplatin, by the addition of hydrogen peroxide 157 
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under darkness, with heating and under constant reflux. 2) The resultant product was converted 158 
to DSCP by the addition of succinic anhydride, also under darkness, heating and reflux 159 
conditions. 3) Finally, DSCP was further converted and stabilized to its bis-propyl ammonium 160 
salt. A schematic representation of the synthetic procedure and characterization are shown in 161 
Supporting Information, A2.  162 
 163 
2.4 Synthesis and characterization of the nanoparticles 164 
 Zn-Pt(IV)-NCPs and the nickel analogous Ni-Pt(IV)-NCPs were obtained by a in situ fast 165 
polymerization reaction of the metal ion (Zn or Ni) with a mixture of two co-ligands: the 166 
platinum prodrug salt and bix. The synthesis of Zn-Pt(IV)-NCPs and Ni-Pt(IV)-NCPs were 167 
performed following previous procedures reported by our research group [19]. In a typical 168 
synthesis Bix (18.2 mg, 0.077 mmol) and Pt(IV) prodrug (50.0 mg, 0.077 mmol) were dissolved 169 
in an aqueous ethanol solution (25ml EtOH + 2 ml miliQ H2O). Under constant stirring at 900 170 
rpm, a solution of Zn(NO3)2 . 6H2O (22.7 mg, 0.077 mmol in 2 mL miliQ H2O) or Ni(NO3)2 . 171 
6H2O (22.3 mg, 0.077 mmol in 2 mL miliQ H2O) were added. The rapid coordination of the co-172 
ligands with the metal ions led to the formation of a fine white and pale blue solids of Zn-173 
Pt(IV)-NCPs and Ni-Pt(IV)-NCPs, respectively, that precipitates in few minutes. The reaction 174 
was maintained under stirring for 30 min and the resultant precipitates were collected by 175 
centrifugation, washed twice with ethanol, and completely dried by lyophilization. A completed 176 
and detailed characterization of the obtained nanoparticles has been summarized in Supporting 177 
Information, A3. 178 
 179 
 180 
2.5 Characterization of the Pt Release kinetics  181 
8 
 
The in vitro release kinetics of Pt from the nanoparticles was studied by the dialysis method. 182 
Briefly, a dialysis bag (MWCO: 3500 Da, 15 x 5 cm) containing 8 mg of Zn-Pt(IV)-NCPs 183 
dispersed in 6 ml sterile PBS (pH 7.4) was placed into 100 ml of PBS solution for 72 hours at 184 
37 ºC and under constant stirring (360 rpm). To determine the release of Pt from the 185 
nanoparticles and diffused through the dialysis bag, aliquots of 500 μL of the external solution 186 
were taken after different incubation times. Samples were kept at 4 ºC, until the Pt concentration 187 
was determined by ICP-MS. Release experiments were performed in triplicate.  188 
  189 
2.6 DNA-binding studies. 190 
DNA-Binding experiments were performed using the pBluescript II plasmid as substrate. 191 
Reactions containing 2 µg of the DNA plasmid were incubated with different concentrations (0, 192 
1, 10, 100 and 500 μM) of the Pt (IV) prodrug or Zn-Pt(IV)-NCPs for 24 hours at 37 ºC in the 193 
absence or presence of ascorbic acid (0.1 μg/μL) in 40 mM Tris-HCL buffer (Ph 7.3) 194 
containning 40 mM NaCl. Samples containing the reducing agent ascorbic acid were 195 
preincubated for 2 hours before the DNA was added to the samples. Reactions with DNA and 196 
different concentrations of cisplatin (0, 0.1, 1, 10 and 50 µM) as control drug were prepared. 197 
Afterwards, gel electrophoresis experiments were performed on agarose gels (0.7% agarose in 198 
Tri-Acetate-EDTA buffer), by using a Bio-Rad horizontal tank connected variable potential 199 
power supply.  200 
 201 
2.7 In vitro studies  202 
Cell culture. Human BE(2)-M17 (ATCC CRL-2267), HeLa (ATCC CL-2) and  MCF-7 (ATCC 203 
HTB-22) cell lines were maintained in Opti-MEM
TM
, in Minimum Essential Medium α (MEM-204 
α) medium, or in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM-F12), 205 
respectively. Media were further supplemented with 10 % (v/v) of heat inactivated fetal bovine 206 
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serum (FBS) and the cells were grown under a highly humidified atmosphere of 95 % air with 5 207 
% CO2 at 37 ºC. 208 
 209 
Cytotoxicity Experiments. The cytotoxicity of Pt(IV) prodrug and Zn-Pt(IV)-NCPs towards 210 
HeLa, BE(2)-M17 and MCF-7 cells was studied by a resazurin-based assay using the 211 
PrestoBlue
TM
 Cell Viability Reagent. The cells were seeded in 96-well plates at a concentration 212 
of 3.0x10
3
 cells/well in the case of HeLa and at 2.0x10
3
 cells/well in the case of BE(2)-M17 and 213 
MCF-7 cells, respectively. After 24 h incubation, cells were then treated with the Pt(IV) prodrug 214 
or with the Zn-Pt(IV)-NCPs nanoparticles at different concentrations ranging from 0 to 540 µM 215 
(referred to the Pt concentration). After 24 and 72 h treatment, aliquots of µl of the 216 
PrestoBlue
TM
 Cell Viability Reagent solution were added to each well and incubated for up to 2 217 
hours at 37 ºC. Fluorescence (γexc=531 nm and γem=572 nm) of each well was measured using a 218 
fluorescence microplate reader. The cytotoxic effect of the Pt(IV) prodrug and Zn-Pt(IV)-NCPs 219 
nanoparticles against the three different cells lines was determined by calculating the half-220 
maximal inhibitory concentration (IC50). Cytotoxicity experiments were performed at least in 221 
triplicate.     222 
 223 
Cellular uptake of Pt. HeLa, BE(2)-M17 and MCF-7 cells were seeded on 60 mm culture 224 
dishes at a cell density of 3.0x10
5
 cells/plate. After 48 h growth, cells were incubated with the 225 
Pt(IV) prodrug and Zn-Pt(IV)-NCPs nanoparticles at a concentration of 75 μM (referred to the 226 
Pt concentration) for 5 h. Immediately before cell recovery, the plates were washed twice with 227 
cold PBS and the cells trypsinized for 10 min at 37 ºC. Afterwards, trypsin was neutralized with 228 
1 volume of fresh medium and aliquots of 10 µl of each cell suspension were collected to count 229 
the number of viable cells present in the samples. For Pt quantitation, cell suspensions were 230 
transferred to 1.5 ml Eppendorf tubes and the samples centrifuged at 12000 rpm for 5 min. 231 
Finally, the supernatants were discarded and the resultant cell pellets were stored at -80 ºC until 232 




Cellular DNA-bound Pt determination. HeLa, BE(2)-M17 and MCF-7 cells were treated with 235 
Pt(IV) prodrug and Zn-Pt(IV)-NCPs nanoparticles similarly as previously described for cellular 236 
uptake experiments. Afterwards, cells were washed twice with cold PBS, scrapped, transferred 237 
to 1.5 ml Eppendorf tubes and centrifuged at 1200 rpm for 5 min. For DNA extraction, the 238 
resultant pellets were resuspended in lysis buffer solution containing 150 mM Tris-HCl (pH 239 
8.0), 100 mM NaCl and 0.5% (w/v) SDS on ice and afterwards centrifuged at 12000 rpm for 15 240 
min and incubated with ribonuclease A (RNase A, 200 μg/mL) for 1 h at 37 ºC. Then, 241 
proteinase K (100 μg/mL) was added followed by an incubation of 3 hours at 56 ºC. A volume 242 
of phenol/chloroform (1:1) was added, mixed gently, and after a centrifugation step, aqueous 243 
phases containing DNA were transferred to sterile tubes. DNA was precipitated with 0.1 244 
volumes of 2 M sodium acetate and 1 volume of absolute ethanol at –20 ºC overnight. DNA 245 
samples were washed with 1 ml of 70 % (v/v) ethanol, dried and resuspended in 20 µl of elution 246 
buffer (10 mM Tris-Cl, 1 mM EDTA, pH 8.0). The concentration of the isolated DNA was 247 
determined by measuring the absorbance at 260 nm using a UV-vis spectrophotometer. Pt-248 
bound to DNA was quantified by ICP-MS. 249 
          250 
2.8 Quantification of Pt, Zn and Ni by ICP-MS  251 
To perform ICP-MS determinations, samples were dissolved in concentrated nitric acid (70% 252 
HNO3) at a concentration of 25 mg/ml and incubated at 50 ºC for 18 h under constant 253 
sonication. After digestion, samples were diluted with purified water to a final 0.5 % (v/v) 254 
HNO3 solution for chemical formula determination of Pt(IV) prodrug and Zn-Pt(IV)-NCPS 255 
nanoparticles, and diluted to a 7 % (v/v) HNO3 solution to analyze the cells and DNA samples 256 
from uptake experiments. Calibration curves of Pt, Zn or Ni were measured from five standard 257 
solutions at different concentrations of each metal (from 20 to 200 ppb for compound samples 258 
and from 0.5 to 10 ppb for cell and DNA samples), previously prepared by diluting certified 259 
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reference metal stock solutions. The concentrations of Pt, Zn or Ni present in the samples were 260 
calculated from the corresponding calibration curve, previously adjusted to a linear regression 261 
model (R
2
>0.99).  262 
 263 
3. Results and discussion   264 
3.1 Synthesis and characterization of Zn-Pt(IV)-NCPs  265 
The schematics for the one-pot synthesis of the Zn-Pt(IV)-NCPs is shown in Fig. 1a. The 266 
nanoparticles were fabricated by the fast polymerization of Zn(NO3)2 with a mixture of two 267 
linker ligands, the bis-propyl ammonium salt of Pt(IV) prodrug (DSCP) and bix, resulting in the 268 
formation of a white precipitate. The Pt(IV) prodrug is used as its propyl ammonium salt form 269 
to favor the coordination of the carboxylic group to the metal ions (Zn or Ni). After 30 minutes, 270 
the resulting solid material was then collected by centrifugation, washed several times with 271 
ethanol, and dried by lyophilization. As shown by scanning electron microscopy (SEM) (Figure 272 
1b-d) Zn-Pt(IV)-NCPs showed spherical morphology and narrow size distribution, whose 273 
diameters ranged between 100-200 nm, yielding an average diameter of 148 ± 48 nm. The study 274 
of the colloidal stability of the nanoparticles in simulated physiological conditions was further 275 
studied by dynamic light scattering (DLS). For this study very stable solution were achieved 276 
dispersing 1 mg/ml of Zn-Pt(IV)-NCPs in a phosphate buffered saline (PBS) at pH 7.4 and 277 
containing 31 mg/ml of bovine serum albumin (BSA) (Figure 1e). In these conditions, DLS 278 
measurements reveal a hydrodynamic diameter of 215 ± 20 nm with an associated 279 
polydispersity index (PDI) of 0.238.  280 
X-ray powder diffraction data for different batches showed that the particles are amorphous 281 
(Fig. S1). The chemical composition of these particles was first determined by energy-282 
dispersive X-ray spectroscopy (EDX), which confirmed that they contain platinum, chloride, 283 
carbon, oxygen, nitrogen and zinc. XPS analysis reveals also the elemental composition and 284 
corroborate the presence of Pt(IV) and Zn(II) metal ions (Fig. S2 and S3). The FT-IR of the Zn-285 
12 
 
Pt(IV)-NCPs support the presence of bix and the Pt(IV) prodrug coordinated to Zn ions (Fig. 286 
S4) as evidenced by the shift of the absorption bands of the carboxylate belonging to the 287 
prodrug ligand from 1625 cm
-1
 to 1586 cm
-1
 observed for the Zn-Pt(IV)-NCPs. Additionally, the 288 




 that appear at 1536 289 
cm
-1
 and 1092 cm
-1
 respectively, indicated the inclusion of the bix ligand into the coordination 290 
polymer network.  291 
 292 
 293 
Fig. 1. Synthesis and characterization of Zn-Pt(IV)-NCPs. a) Schematic of Zn-Pt(IV)-NCPs 294 
synthesis. b-c) Scanning electron microscopy (SEM) images of Zn-Pt(IV)-NCPs. d) Particle size 295 
distribution extracted from SEM images. e) Size distribution of the nanoparticles measured in 296 
triplicate by DLS in PBS (pH 7.4) and in the presence of BSA. Note that the peak showed 297 
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around 10 nm corresponds to BSA and the one that appears at 200-300 nm is attributed to the 298 
nanoparticles.  299 
 300 
The elemental analysis of the resulting nanoparticles (Table S1) and ICP-MS results for the 301 
measurement of metal contain (See Supporting Information, A3.1) are consistent with the 302 
proposed coordination polymer formation with formula [{Zn(Bix)(DSCP)(H2O)2}·EtOH] 303 
corroborating the presence of one bix ligand, one Pt(IV) prodrug molecule and one Zn metal ion 304 
per monomer unit (Fig. S2). Additionally, the chemical formula is completed with one molecule 305 
of EtOH and two water molecules, the later presumably in the coordination sphere of Zn ions. 306 
In agreement, the nanoscale coordination polymer contains 56.6 ± 0.4 wt.% of the Pt(IV)-307 
prodrug, 7.7 ± 0.5 wt.% of Zn and 26.8 ± 0.6 wt.% of bix. The TGA analysis (Fig. S5) 308 
corroborate the presence of the solvent molecules since the thermal decomposition showed a 309 
weight loss of 4.72% in the temperature range of 25-150ºC which fits with the loss of 1 310 
molecule of EtOH (calculated weight loss = 5.02%), and another weight loss of 58.51% within 311 
the temperature range of 150-900ºC which is attributed to the loss of two water molecules and 312 
decomposition of the ligand bix and the co-ligand DSCP (calculated weight loss for 2 molecules 313 
of water + 1 molecule of bix + 2 molecule of DSCP = 66.65%). The discrepancy of 8.14% 314 
between the calculated and experimental values may be due to the undecomposed fraction of 315 
thermally stable DSCP. The remaining weight, close to 35%, would correspond to the non-316 
volatile metal oxides generated after burning completely the sample. Fluorescence microscopy 317 
images of the resulting nanoparticles showed an intense blue luminescence (peak centered at 318 
approximately 405 nm) when the nanoparticles were excited at 355 nm (Fig. S6). This 319 
fluorescence emission is typical for Zn-Bix coordination polymers what demonstrates the 320 
coordination of bix with Zn(II) [24] . These optical properties make Zn(bix)-based polymers 321 
potential blue fluorescent materials and suggests its possible application for biomedical 322 




3.2 In vitro drug release  325 
When Zn-Pt(IV)-NCPs (1 mg/ml) is dispersed in BSA-containing PBS buffer (31 mg/ml), the 326 
nanoparticles present notable stability up to 24 h incubation, indicating that the presence of BSA 327 
improves the colloidal stability of the nanoparticles. Under these conditions, the drug release 328 
profile of Pt from Zn-Pt(IV)-NCPs was studied for 24 h at 37°C by using dialysis bag method. 329 
As shown in Fig. 2, we observed a fast release of the drug during the initial hours, reaching 330 
around 50% Pt release at 2 hours and 80% of the total Pt release after 7 hours. Then, a 331 
sustainable slow release (~ 10%) takes place during the subsequent 14 hours. 332 
 333 
Fig. 2. In vitro release kinetics of Pt from Zn-Pt(IV)-NCPs nanoparticles. Experiment was 334 
performed in PBS containing 31 mg/ml BSA at pH 7.4 at 37 º in triplicate.  335 
 336 
The initial fast release is suggested to be related to the fast degradation of the first layers (soft 337 
polymer), meanwhile the more dense core offers an slow release for the remaining material. The 338 
overall release fit well with similar systems previously described [16, 17], and give us an 339 
information about the chemical stability of the NCPs in solution in physiological conditions. In 340 
order to improve their solubility in high-ionic-strength solutions, the nanoparticles were coated 341 
with BSA as stabilizer. Serum albumins are attractive natural proteins because they are present 342 
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in large amounts in biological fluids (such the human serum), or in fetal bovine serum (FBS), 343 
and is commonly used supplement for cell culture media. The use of BSA for stabilizing 344 
colloidal dispersions of nanoparticles is a common procedure to increase the stability of 345 
different nanoconstructs in physiological media. Alternativeley, other coating materials such as 346 
silica, lipids or PEG polymers have been used for stabilize Pt(IV)-based NCPs and increase 347 
their colloidal suspensions [16, 25, 26]. 348 
3.3 DNA-binding studies   349 
To investigate the effects and interaction of the Pt(IV) prodrug and Zn-Pt(IV)-NCPs 350 
nanoparticles on a double- stranded DNA, pBlueScript plasmid was used as the DNA substrate, 351 
and the resulting DNA-Pt complexes obtaining after treatment were analyzed by an agarose-gel 352 
electrophoresis (Fig. S7). To perform the experiments, different concentrations of the Pt(IV) 353 
prodrug or Pt(IV) prodrug-based nanoparticles were incubated for 24 h at 37 ºC in the absence 354 
or presence of ascorbic acid. Ascorbic acid (AA) was added to improve the activation of the 355 
prodrug through the reduction of Pt(IV) into active Pt(II) as reported previously [27]. In 356 
addition, different concentrations of cisplatin were assayed for comparison purposes. The effect 357 
of binding of these compounds was determined by their ability to alter the electrophoretic 358 
mobility of a plasmid DNA, which presents two majoritarian forms under native conditions: a 359 
supercoiled closed circular form (CCC) and an open circular form (OC) [27, 28].  360 
When the Pt(IV) prodrug or Zn-Pt(IV)-NCPs were incubated in the absence of AA, no 361 
important effects on DNA migration were observed up to concentrations of 100 μM (Fig. S7). 362 
By contrast, the gold standard drug cisplatin caused important effects on the mobility of both 363 
the CCC and OC forms of the plasmid DNA at concentrations higher than 10 µM (i.e. 10 and 50 364 
µM) (Fig. S7). In a similar manner, the highest concentration assayed of the Pt(IV) prodrug (i.e. 365 
500 μM)  did not caused changes in the mobility of the OC and CCC forms in the absence of 366 
AA (Fig. 3). Interestingly, we observed a clear shift of the two OC and CCC bands in the case 367 
of the DNA treated with the nanoparticles at the same concentration (see Fig. 3), suggesting a 368 
partial activation of the Pt(IV) prodrug from the nanostructured coordination polymer in the 369 
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absence of reductant. These bands shift was associated with partial disappearance of the 370 
brightness of both OC and CC DNA forms.  371 
 372 
Fig. 3. Agarose gel electrophoresis of a pBluescript II plasmid DNA treated with the Pt(IV) 373 
prodrug or Zn-Pt(IV)-NCPs. In both cases the concentration assayed was 500 µM as referred to 374 
the Pt concentration and the samples were incubated for 24 h at 37 ºC in 50 mM Tris-HCl (pH 375 
7.3) buffer containing 40 mM NaCl in the absence or presence of 0.1 mg/ml ascorbic acid 376 
(+AA). Pure pBluescript II plasmid DNA (Control DNA) and pBluescript II plasmid DNA 377 
incubated with 50 µM cisplatin (Cisplatin-Pt(II)-) were prepared as control conditions. 378 
 379 
In the presence of ascorbic acid (AA), the Zn-Pt(IV)-NCPs nanoparticles clearly altered the 380 
mobility of the plasmid DNA in comparison with the same treatment in the absence of reducing 381 
agent (see Fig. 3). Furthermore, we observed an almost complete disappearance of the signal of 382 
both OC and CC DNA forms. These results indicate that AA accelerates the conversion of the 383 
Pt(IV) prodrug present in the nanostructured coordination polymer to more active Pt (II) 384 
species, and points to a redox-dependent mechanism of activation. It is well known that the 385 
presence of a reducing environment inside the cells facilitates the intracellular reduction of 386 
Pt(IV) prodrugs to active Pt(II) species. This step is thought to be essential for the anticancer 387 
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activity of these agents, and involves the loss of the two axial ligands present in the prodrug 388 
[14]. Moreover, the use of nanoparticles containing Pt(IV) polymer conjugates is an interesting 389 
strategy to preserve the inactive Pt(IV) complex until a reducing environment generates the 390 
activate Pt(II) species. Yang et al. demonstrated by electrochemical studies that platinum(IV)-391 
coordinated polymers can more easily lose the axial ligands and be reduced to the corresponding 392 
Pt(II) active drug in an acidic environment [29]. In the case of the free Pt(IV) prodrug, 393 
incubation with AA clearly altered the mobility of the plasmid DNA compared to the non-394 
treated control or with the DNA treated with the Pt(IV) prodrug alone. As shown in Fig. 3, 395 
when AA is present in the medium the CCC form runs slightly slower compared to 396 
aforementioned conditions, demonstrating a slight progressive unwinding of the supercoiled 397 
DNA. This shift in the migration of the CCC form was accompanied by an increase in the 398 
mobility of the OC form, which is compatible with the formation of cisplatin 1, 2 intrastrand 399 
crosslinks [30]. While the Pt(II) produced upon the activation of the Pt(IV) prodrug are 400 
interacting with the DNA, the gel analyses show that they do not form the same complexes 401 
induced by the well-known cisplatin (Fig. 3). This phenomenon has been previously 402 
demonstrated by other authors for different Pt(IV) prodrugs [27]. In agreement, it has been 403 
reported that Pt(IV) complexes can platinate DNA in their oxidized form through the formation 404 
of cytotoxic lesions induced by ligand substitution [14].  405 
Taken together, these results from DNA-binding experiments indicate that the Pt(IV) prodrug 406 
and the Zn-Pt(IV)-NCPs are interacting with DNA in a concentration-dependent manner. 407 
Remarkably, we also show that the Zn-Pt(IV)-NCPs do not require the presence of AA to 408 
interact with the DNA, a difference with the non-nanostructured Pt(IV) prodrug. Moreover, 409 
partial banishing of the bands associated with the plasmid DNA indicates an interaction of the 410 
nanoparticles with the DNA. Such binding might be mediated via electrostatic interactions with 411 
the negatively charged phosphate backbone and the electrical charges of the nanostructured 412 
coordination polymer. This differential interaction may lead to the aggregation of the DNA 413 
limiting the entrance and migration of this Zn-Pt(IV)-NCPs-DNA complexes in the gel. 414 
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Considering these results, we suggest a different mode of activation and interaction between the 415 
free Pt(IV) prodrug and the nanoparticles with the plasmid DNA.  416 
 417 
3.4 In vitro Cytotoxicity against cancer cells lines  418 
Human cervical cancer, neuroblastoma, and human adenocarcinoma cells lines (HeLa, BE(2)-419 
M17 and MCF-7, respectively) were used to test the cytotoxicity of the Pt(IV) prodrug and Zn-420 
Pt(IV)-NCPs nanoparticles after 24 h and 72 h treatment. For comparison purposes, cisplatin as 421 
control was evaluated under the same experimental conditions. The resultant IC50 values are 422 
summarized in Table 1.  423 
 424 
Table 1. Cytotoxicity of cisplatin, Pt(IV) prodrug and Zn-Pt(IV)-NCPs against three different 














Cell line 24 h               24 h                 72 h     24 h                  72 h 
HeLa 3.5 ± 0.9    >540            431 ± 82  218 ± 21           130 ± 27 
MCF-7 2.8 ± 0.4  >540            296 ± 31  249 ± 64              59 ± 8 
BE(2)-M17 5.5 ± 0.7  >540            494 ± 66  218 ± 21            133 ± 8  
1 
Cell viability in the presence of the indicated compound and referred to Pt concentration.  
 425 
After 24 h treatment, the Pt(IV) prodrug did not exhibited cytotoxicity against HeLa, MCF-7 or 426 
BE(2)-M17 cells, with IC50 values higher than 540 μM. By contrast, the Zn-Pt(IV)-NCPs 427 
displayed a slight enhanced antitumoral efficacy against the three cell lines, with IC50 values 428 
below 300 μM. This effect was much evident at longer incubation times. Thus, after 48 h 429 
incubation, the IC50 values for the Zn-Pt(IV)-NCPs nanoparticles against HeLa, MCF-7 or 430 
BE(2)-M17 cells were 1.7-fold, 4.2-fold and 1.6-fold lower than the Pt(IV) prodrug, 431 
respectively. This indicates that nanostructuration of a drug increases its cytotoxic effect, and 432 
suggests that maintaining the therapeutic agent within a nanoparticle the anticancer drug can be 433 
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protected from degradation before cell internalization or, alternatively, provide a more favorable 434 
uptake pathway for the cells via endocytosis followed by lysosomal degradation, which can 435 
potentially accelerate the conversion of Pt(IV) to its active form Pt(II). However, although the  436 
IC50 values for Zn-Pt(IV)-NCPs decreases with incubation time, slight differences between 437 
different cell lines were observed. As observed, the therapeutic action is also dependent on the 438 
cell type. Meanwhile for HeLa and BE(2)-M17 neuroblastoma cell lines the IC50 values 439 
obtained with cisplatin, Pt(IV) prodrug and Zn-Pt(IV)-NCPs are similar, in the case of MCF7 440 
cells the toxicity is notably low in all cases.  441 
To assess whether the differences in the cytotoxicity observed between the Zn-Pt(IV)-NCPs and 442 
the Pt(IV) prodrug can be attributed to the Zn metal ion present in the nanoparticles, a second 443 
generation of Pt-based NCPs incorporating Ni as metal node were synthesized and 444 
characterized. Characterization of these nanoparticles (Ni-Pt(IV)-NCPs,) revealed its analogous 445 
morphology and chemical composition  in comparison with Zn-Pt(IV)-NCPs (See Supporting 446 
Information, Fig. S8-S10 and Table S2). The characterization by XRD revealed the amorphous 447 
nature of the nanoparticles (Fig. S11) and SEM analysis showed spherical shaped morphology 448 
with mean size of ~200 nm (Fig. S12). DLS measurements confirmed the stability of the 449 
nanoparticles under physiological conditions (PBS, 7.4 pH with 31 mg/ml BSA) having a 450 
hydrodynamic diameter close to 250 nm.   451 
As observed in Table 2 the substitution of Zn by Ni in the nanoparticles does not affect the 452 
cytotoxicity, what discard the cytotoxic effect attributed to the metal node. As a control probe, 453 
Zn(NO3)2 . 6H20 and Ni(NO3)2 . 6H20  salt were tested and the results indicated low levels of 454 
citoxicity (Supporting Information, Table S3). 455 
 456 
 457 












Cell line     24 h                  72 h     24 h                  72 h 
HeLa 302 ± 28           117 ± 24 218 ± 21           130 ± 27 
MCF-7 339 ± 44               52 ± 6 249 ± 64              59 ± 8 
BE(2)-M17 462 ± 46            81 ± 13  218 ± 21            133 ± 8  
1 




3.5 Intracellular uptake and quantitation of DNA-bound Pt 460 
Cellular uptake of the free Pt(IV) prodrug or nanostructured as NCPs was studied in HeLa, 461 
BE(2)-M17 and MCF-7 cells, using ICP-MS as analytical technique to determine the amount of 462 
platinum present in the intracellular medium. The cells were previously incubated in the 463 
presence of 75 μM, of the Pt(IV) prodrug or Zn-Pt(IV)-NCPs, in terms of Pt concentration, for 5 464 
h. Cisplatin was used as control using the same concentration based on amount of platinum and 465 
under the same experimental conditions. As shown in Fig. 4, there was no statistically 466 
significant difference concerning the amount of Pt detected inside the cells between the 467 




Fig. 4. Cellular uptake of Pt determined by ICP-MS. HeLa, BE(2)-M17 and MCF-7 cells were 470 
treated in the presence of Pt(IV) prodrug or Pt(IV)-NCPs at 75 µM for 6 h. After incubation, the 471 
total amount of internalized Pt was determined by ICP-MS. Data is shown as mean ± sd of three 472 
independent experiments performed in triplicate. An Unpaired t-test was performed to compare 473 
the Pt uptake between the three different agents: ns, not significative (p> 0.05).  474 
 475 
These unexpected results do not correlate with the cytotoxicity effect if we attribute the 476 
cytotoxic effect to the amount of platinum. If fact it was expected a higher concentration of Pt 477 
inside the cells when the NCPs is used as previously observed with other kind of NCPs [21, 25]. 478 
In light of this, we performed additional uptake experiments to acquire a more precise 479 
quantification of the platinum that had not only reached the inner part of the cell, but also 480 
reached the nucleus and interacted with the nuclear double-stranded DNA (final target) in order 481 
to understand the higher cytotoxic effect associated to the nanostructured Pt(IV) prodrug in 482 
comparison to the free Pt(IV) prodrug.   483 
In this second assay, the experimental conditions remains the same that the previous uptake 484 
study, but in this case the nuclear DNA of cells treated with cisplatin (control cells), Pt(IV) 485 
prodrug or Zn-Pt(IV)-NCPs was further purified and isolated. Then, the amount of Pt bound to 486 
the DNA was quantified by ICP-MS (see experimental section for more details). As shown in 487 
Fig. 5, results showed significantly higher concentrations of Pt bound to the DNA of cells 488 
treated with NCPs in comparison to those treated with the free Pt(IV) prodrug. As expected, the 489 
Pt concentrations in both cases were much lower compared to the treatment with the 490 




Fig. 5. Concentration of DNA-bound Pt determined by ICP-MS. HeLa, BE(2)-M17 and MCF-7 493 
cells were treated in the presence of Pt(IV) prodrug or Zn-Pt(IV)-NCPs at 75 µM for 5 h. As 494 
control condition, cells were also treated with an equivalent Pt concentration of cisplatin.  After 495 
treatment, the nuclear DNA was extracted from the cells, hydrolyzed with concentrated nitric 496 
acid and subjected to ICP-MS. Data is shown as mean ± Sd of three independent experiments 497 
performed in triplicate. An Unpaired t-test was performed to compare the DNA-bound Pt 498 
between the three different agents: * p< 0.05; ** p< 0.01; *** p<0.0001. 499 
 500 
Therefore, these results bring light concerning the cytotoxic effect of the different formulations. 501 
These experimental data are in agreement with the observed cytotoxicity. Even that the amount 502 
of platinum internalized in cells was not achieving significant differences between the 503 
nanostructured and non-nanostructured Pt(IV) prodrug, platinum is actually more likely to reach 504 
the nuclei of cells when the prodrug is nanostructured, showing an enhancement in the cytotoxic 505 
effect upon nanostructuration. Shen and coworkers [29] investigated the kinetics and 506 
mechanism of reduction of Pt(IV) prodrug monomers and its derived Pt(IV)-coordinate 507 
polymers under different environments. These researchers showed that Pt(IV) in the polymers 508 
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was much easier reduced to Pt(II) in acidic conditions (such those found inside the cells in 509 
lysosomes/endosomes). Our results are, in line with this recent data, which suggest a different 510 
activation mechanism of the Pt(IV) prodrug upon the formation of the nanostructured 511 
coordination polymer. This hypothesis is consistent with DNA-binding experiments, in which 512 
we demonstrated that Zn-Pt(IV)-NCPs is indeed able to alter the mobility of plasmid DNA in 513 
the absence of reducing agent, while under the same conditions, the Pt(IV) prodrug monomer 514 
did not changed the migration of the plasmid DNA (Fig. 3). A number of previous studies 515 
demonstrated an enhanced effect of Pt(IV) prodrugs after its nanostructuration, however none of 516 
these works investigated the intracellular levels of Pt inside the cells, or neither the conversion 517 
of the prodrug.      518 
 519 
Nanoparticles can often be engineered to have enhanced efficacy in the delivery of 520 
chemotherapeutic agents compared the parent drugs. One broad strategy in the nanodelivery of 521 
these drugs involves the study of cellular uptake, which usually correlates with the cytotoxic 522 
effect. In this report we show that the intracellular levels of Pt after treatment with a 523 
nanostructured Pt(IV) prodrug do not correlate with cytotoxicity, and highlight the importance 524 
of the study of other factors such the chemical interactions, activation mechanism and/or 525 
degradation of the nanostructured materials developed for specific platinum delivery.      526 
  527 
 528 
4, Conclusions 529 
In this study, we have successfully designed and synthetized nanostructured coordination 530 
polymer particles (NCPs) based on the polymerization of a Pt(IV) prodrug (DSCP), using Zn 531 
ions as metal nodes and bix as a coligand to induce the polymerization. The resulting 532 
nanoparticles (Zn-Pt(IV)-NCPs) are stable in physiologic conditions, and show an slow and 533 
sustainable release of the Pt(IV) prodrug during several hours. The cytotoxicity studies revealed 534 
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the enhanced antitumor activity of the nanoparticles respect to the free prodrug against the 535 
different cancer cell lines studied; HeLa, BE(2)-M17 and MCF-7. Although the enhanced 536 
efficacy demonstrated by the nanoparticles respect to the free prodrug, no increase in the total 537 
cellular uptake of Pt was observed. By contrast, the amount of Pt associated to the nuclear DNA 538 
of the cells treated with the nanoparticles was found to be higher than those cells treated with 539 
the free prodrug. The change of Zn by Ni in the NCPs formulation corroborated the non-existent 540 
toxicity related to the metal node. The obtaining results indicate that the nanostructuration have 541 
not a direct effect in the cellular uptake, but the polymerization of the Pt(IV) prodrug implies in 542 
some way a more facile conversion of the prodrug to the active cisplatinum molecule and the 543 
enhance of the cytotoxicity. The presented results have shown how the nanostructuration of a 544 
therapeutic agent or a prodrug can modify the bioavailability of the active specie and increase 545 
the therapeutic action based in different mechanism in comparison with non-structured 546 
molecules. In virtue of what was observed, many more efforts should be addressed to determine 547 
the different mechanisms of action of nanostructured materials and try to rationalize how the 548 
nanostructuration can modify the nature of the active specie. 549 
 550 
Conflict of interest  551 
The authors declare that they have no conflicts of interest with the contents of this article. 552 
 553 
Acknowledgments 554 
This work was supported by project MAT2012-38318-C03-02,MAT2015-70615-R, BIO2013-555 
44973-R and BIO2016-78057-R from theSpanish Government and by FEDER–European 556 
Commission funds.ICN2 acknowledges support from the Severo Ochoa Programme of 557 
theSpanish Ministry of Economy, Industry and Competitiveness (MINECO,Grant SEV-2013-558 
25 
 
0295). The ICN2 is funded by the CERCA programme/Generalitat de Catalunya. Authors 559 
would also like to acknowledge thesupport of the TRANSAUTOPHAGY COST Action, 560 




[1] B. Rosenberg, L. VanCamp, J.E. Trosko, V.H. Mansour, Platinum compounds: a new class 565 
of potent antitumour agents, Nature 222 (1969) 385-386. 566 
[2] L.A. Zwelling, T. Anderson, K.W. Kohn, DNA-protein and DNA interstrand cross-linking 567 
by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation 568 
to cytotoxicity, Cancer research 39 (1979) 365-369. 569 
[3] S. Dasari, P.B. Tchounwou, Cisplatin in cancer therapy: molecular mechanisms of action, 570 
European journal of pharmacology 740 (2014) 364-378. 571 
[4] J.T. Hartmann, H.P. Lipp, Toxicity of platinum compounds, Expert opinion on 572 
pharmacotherapy 4 (2003) 889-901. 573 
[5] T. Karasawa, P.S. Steyger, An integrated view of cisplatin-induced nephrotoxicity and 574 
ototoxicity, Toxicology letters 237 (2015) 219-227. 575 
[6] A. Avan, T.J. Postma, C. Ceresa, A. Avan, G. Cavaletti, E. Giovannetti, G.J. Peters, 576 
Platinum-induced neurotoxicity and preventive strategies: past, present, and future, The 577 
oncologist 20 (2015) 411-432. 578 
[7] L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, O. Kepp, M. Castedo, G. 579 
Kroemer, Molecular mechanisms of cisplatin resistance, Oncogene 31 (2012) 1869-1883. 580 
[8] A.R. de Biasi, J. Villena-Vargas, P.S. Adusumilli, Cisplatin-induced antitumor 581 
immunomodulation: a review of preclinical and clinical evidence, Clinical cancer research : an 582 
official journal of the American Association for Cancer Research 20 (2014) 5384-5391. 583 
26 
 
[9] I. Ali, W.A. Wani, K. Saleem, A. Haque, Platinum compounds: a hope for future cancer 584 
chemotherapy, Anti-cancer agents in medicinal chemistry 13 (2013) 296-306. 585 
[10] S. Dilruba, G.V. Kalayda, Platinum-based drugs: past, present and future, Cancer 586 
chemotherapy and pharmacology 77 (2016) 1103-1124. 587 
[11] F. Meng, N. Han, Y. Yeo, Organic nanoparticle systems for spatiotemporal control of 588 
multimodal chemotherapy, Expert opinion on drug delivery 14 (2017) 427-446. 589 
[12] X. Duan, C. He, S.J. Kron, W. Lin, Nanoparticle formulations of cisplatin for cancer 590 
therapy, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 8 (2016) 776-591 
791. 592 
[13] C. He, D. Liu, W. Lin, Nanomedicine Applications of Hybrid Nanomaterials Built from 593 
Metal-Ligand Coordination Bonds: Nanoscale Metal-Organic Frameworks and Nanoscale 594 
Coordination Polymers, Chemical reviews 115 (2015) 11079-11108. 595 
[14] T.C. Johnstone, K. Suntharalingam, S.J. Lippard, The Next Generation of Platinum Drugs: 596 
Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs, Chemical reviews 116 597 
(2016) 3436-3486. 598 
[15] N. Bertrand, J. Wu, X.Y. Xu, N. Kamaly, O.C. Farokhzad, Cancer nanotechnology: The 599 
impact of passive and active targeting in the era of modern cancer biology, Adv Drug Deliver 600 
Rev 66 (2014) 2-25. 601 
[16] W.J. Rieter, K.M. Pott, K.M. Taylor, W. Lin, Nanoscale coordination polymers for 602 
platinum-based anticancer drug delivery, Journal of the American Chemical Society 130 (2008) 603 
11584-11585. 604 
[17] L. Amorin-Ferre, F. Busque, J.L. Bourdelande, D. Ruiz-Molina, J. Hernando, F. Novio, 605 
Encapsulation and release mechanisms in coordination polymer nanoparticles, Chemistry 19 606 
(2013) 17508-17516. 607 
27 
 
[18] F. Novio, N. Simmchen, N. Vázquez-Mera, L. Amorín-Ferrer, D. Ruiz-Molina, 608 
Coordination polymer nanoparticles in medicine, Coord. Chem. Rev. 257 (2013) 8. 609 
[19] F. Novio, J. Lorenzo, F. Nador, K. Wnuk, D. Ruiz-Molina, Carboxyl group (-CO2 H) 610 
functionalized coordination polymer nanoparticles as efficient platforms for drug delivery, 611 
Chemistry 20 (2014) 15443-15450. 612 
[20] R.C. Huxford-Phillips, S.R. Russell, D.M. Liu, W.B. Lin, Lipid-coated nanoscale 613 
coordination polymers for targeted cisplatin delivery, Rsc Advances 3 (2013) 14438-14443. 614 
[21] D.M. Liu, C. Poon, K.D. Lu, C.B. He, W.B. Lin, Self-assembled nanoscale coordination 615 
polymers with trigger release properties for effective anticancer therapy, Nature 616 
communications 5 (2014). 617 
[22] N.N. Adarsh, F. Novio, D. Ruiz-Molina, Coordination polymers built from 1,4-618 
bis(imidazol-1-ylmethyl)benzene: from crystalline to amorphous, Dalton transactions 45 (2016) 619 
11233-11255. 620 
[23] F. Novio, J. Lorenzo, F. Nador, K. Wnuk, D. Ruiz-Molina, Carboxyl Group (-CO2H) 621 
Functionalized Coordination Polymer Nanoparticles as Efficient Platforms for Drug Delivery, 622 
Chem-Eur J 20 (2014) 15443-15450. 623 
[24] I. Imaz, J. Hernando, D. Ruiz-Molina, D. Maspoch, Metal-organic spheres as functional 624 
systems for guest encapsulation, Angewandte Chemie 48 (2009) 2325-2329. 625 
[25] R.C. Huxford-Phillips, S.R. Russell, D. Liu, W. Lin, Lipid-coated nanoscale coordination 626 
polymers for targeted cisplatin delivery, RSC advances 3 (2013) 14438-14443. 627 
[26] D. Liu, C. Poon, K. Lu, C. He, W. Lin, Self-assembled nanoscale coordination polymers 628 
with trigger release properties for effective anticancer therapy, Nature communications 5 (2014) 629 
4182. 630 
[27] Y. Shi, S.A. Liu, D.J. Kerwood, J. Goodisman, J.C. Dabrowiak, Pt(IV) complexes as 631 
prodrugs for cisplatin, Journal of inorganic biochemistry 107 (2012) 6-14. 632 
28 
 
[28] J. Ruiz, J. Lorenzo, L. Sanglas, N. Cutillas, C. Vicente, M.D. Villa, F.X. Aviles, G. Lopez, 633 
V. Moreno, J. Perez, D. Bautista, Palladium(II) and platinum(II) organometallic complexes with 634 
the model nucleobase anions of thymine, uracil, and cytosine: antitumor activity and 635 
interactions with DNA of the platinum compounds, Inorganic chemistry 45 (2006) 6347-6360. 636 
[29] J. Yang, W. Liu, M. Sui, J. Tang, Y. Shen, Platinum (IV)-coordinate polymers as 637 
intracellular reduction-responsive backbone-type conjugates for cancer drug delivery, 638 
Biomaterials 32 (2011) 9136-9143. 639 
[30] A. Binter, J. Goodisman, J.C. Dabrowiak, Formation of monofunctional cisplatin-DNA 640 
adducts in carbonate buffer, Journal of inorganic biochemistry 100 (2006) 1219-1224. 641 
 642 
 643 
